We are inspiring human belief in a healthier world
Our founding mission is to make highly quality medicines affordable and accessible to the world
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Our mission to enable access to affordable medicines and improve lives flow from the top
Expanding our presence to serve more people and create meaningful impact
Being acknowledged for our efforts motivates our entire team
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
The path to serving patients better
World-class and differentiated portfolio in chronic therapy areas
Achieving a sustainable health equity
Fully integrated services across the value chain
Committed to transforming standards of care
Researching areas of unmet medical need
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Research excellence for us means to invest in the future of health for the world
We invest in cutting edge research to develop new cures for challenging diseases
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Legacy of trust
Growing better, together
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Aiming for a sustainable environment
A constant focus on sustainable environment with focus on health and safety
A steadfast commitment to enable communities
Hetero aims to report comprehensively and transparently for all stakeholders
Find range of resources including press releases, featured stories and information on social media channels
Access our latest press releases and resources for News and Media section
Discover the stories that enumerate the way we understand disease and develop medicines
Latest media releases and statements in the Hetero newsroom
Browse and download multimedia resources for use
Notices
Back
Hyderabad, India – March 27, 2026: Hetero today announced the export launch of its generic semaglutide portfolio, marking a significant step toward expanding access to GLP-1 therapies for the treatment of type 2 diabetes and obesity.
The launch represents the beginning of a strategic, multi-year global rollout across more than 75 countries, as part of Hetero's focus on improving access to advanced cardio-metabolic therapies. Initial launches are underway in Africa, Asia, and the Middle East, with further rollouts planned, subject to regulatory approvals.
The injectable semaglutide therapies will be marketed under the brand names Truglyx, Rolmodl and Moto G across markets.
Hetero is currently awaiting approval from India's national regulator, CDSCO, following the completion of clinical trials in type 2 diabetes and obesity. Launch in India is anticipated post regulatory approvals.
Dr. Vamsi Krishna Bandi, Managing Director, Hetero, said: "With this launch, our goal is to offer a high-quality, affordable generic semaglutide to patients across emerging markets. We have developed a single, global-quality product platform, reflecting our capabilities in advanced product development and the manufacturing of complex generics. Leveraging our established commercial networks across Asia, the Middle East, Africa, and Latin America, we remain focused on expanding access to high-quality therapies in the diabetes and metabolic care space, while ensuring a consistent global supply."
The portfolio will be available in multi-dose disposable pen devices designed in line with innovator formats, and across multiple dose strengths including 0.25 mg, 0.5 mg, 1 mg, 2 mg, 1.7 mg and 2.4 mg, supporting both type 2 diabetes and weight management, and enabling flexible, patient-centric dosing.
About Hetero
Hetero is a leading global pharmaceutical company focused on the development, manufacturing and commercialization of Active Pharmaceutical Ingredients (APIs) and generic formulations.
Headquartered in Hyderabad, India, Hetero operates in more than 145 countries and is a trusted partner to multinational pharmaceutical companies and global procurement agencies. For more information on Hetero, please visit www.hetero.com.
In case of any enquiry/clarification, contact: Corpcomm@hetero.com +91 040 23704923
Disclaimer: This press release is for informational purposes only and is not intended for promotional use.